April 20, 2025 a 07:31 am
ABBV: Fundamental Ratio Analysis - AbbVie Inc.
AbbVie Inc. is a strong player in the pharmaceutical industry with a diverse portfolio of products. The company has shown consistent growth, but faces competition in key therapeutic areas. Investors are optimistic due to its solid pipeline and strategic partnerships.
Fundamental Rating
The fundamental rating of AbbVie Inc. shows mixed results with strong scores in some areas but weaker in others.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
AbbVie's historical scores provide a glimpse into past performance trends.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-17 | 3 | 5 | 5 | 4 | 1 | 1 | 1 |
| 2024-04-17 | 0 | 5 | 5 | 4 | 1 | 1 | 1 |
Analyst Price Targets
Analysts provide a future outlook for AbbVie's stock price, reflecting optimism and potential risks.
| High | Low | Median | Consensus |
|---|---|---|---|
| $226 | $210 | $217.5 | $217.75 |
Analyst Sentiment
The sentiment among analysts suggests a strong buy consensus with some recommending holding positions.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 26 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Despite the challenges in the competitive pharmaceutical landscape, AbbVie Inc. has proven resilience in maintaining strong scores in critical areas like DCF and ROE. The current analyst outlook reflects a positive consensus for ABBV, mainly categorized as a 'Buy'. While fundamental ratings show mixed results, the company's strategic initiatives indicate a potential for future growth. Investors may find value in today's price, but should remain vigilant for market shifts and competitive pressures.